Drug Profile
Research programme: antithrombotic peptides - Bioxodes
Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Free University of Brussels
- Developer Bioxodes
- Class Peptides
- Mechanism of Action Serine protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Thrombosis(Prevention) in Belgium (IV, Injection)
- 08 Jan 2014 Preclinical trials in Thrombosis (prevention) in Belgium (IV)